Treatments of Inflammatory Bowel Disease Toward Personalized Medicine

Overview

Journal Arch Pharm Res

Specialty Pharmacology

Date 2021 Mar 25

PMID 33763844

Citations 10

Authors

Ki-Uk Kim

Jisu Kim

Wan-Hoon Kim

Hyeyoung Min

Chang Hwan Choi

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory disease characterized by intestinal inflammation and epithelial injury. For the treatment of IBD, 5-aminosalicylic acids, corticosteroids, immunomodulators, and biologic agents targeting tumor necrosis factor (TNF)-α, α4β7-integrin, and interleukin (IL)-12/23 have been widely used. Especially, anti-TNF-α antibodies are the first biologic agents that presently remain at the forefront. However, 10-30% of patients resist biologic agents, including anti-TNF-α agents (primary non-responder; PNR), and 20-50% of primary responders develop treatment resistance within one year (secondary loss of response; SLR). Nonetheless, the etiologies of PNR and SLR are not clearly understood, and predictors of response to biologic agents are also not defined yet. Numerous studies are being performed to discover prediction markers of the response to biologic agents, and this review will introduce currently available therapeutic options for IBD, biologics under investigation, and recent studies exploring various predictive factors related to PNR and SLR.

Citing Articles

Tailoring Mesalazine Nanosuspension Using Chitosan Polyelectrolyte Complexes with Alginate and Alginate/Hydroxypropyl-Methylcellulose Phthalate.

Pereira A, Aparecida J, Ramalho M, Ferreira L, Gremiao M Pharmaceutics. 2025; 16(12.

PMID: 39771469 PMC: 11676705. DOI: 10.3390/pharmaceutics16121489.

Marine Microorganism Molecules as Potential Anti-Inflammatory Therapeutics.

Lasalo M, Jauffrais T, Georgel P, Matsui M Mar Drugs. 2024; 22(9).

PMID: 39330286 PMC: 11433570. DOI: 10.3390/md22090405.

Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study.

Allocca M, Catalano G, Savarino E, Chaparro M, Levartovsky A, Michalopoulos G United European Gastroenterol J. 2024; 12(5):543-551.

PMID: 38419274 PMC: 11176899. DOI: 10.1002/ueg2.12492.

Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study.

Zhao J, Chen R, Luo M, Gong H, Li K, Zhao Q Diabetol Metab Syndr. 2024; 16(1):12.

PMID: 38191425 PMC: 10775535. DOI: 10.1186/s13098-023-01252-1.

Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.

Vermeire S, Feagan B, Peyrin-Biroulet L, Oortwijn A, Faes M, de Haas A J Crohns Colitis. 2023; 18(1):54-64.

PMID: 37540206 PMC: 10821704. DOI: 10.1093/ecco-jcc/jjad123.

References

Aden K, Rehman A, Waschina S, Pan W, Walker A, Lucio M . Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2019; 157(5):1279-1292.e11. DOI: 10.1053/j.gastro.2019.07.025. View

Almradi A, Hanzel J, Sedano R, Parker C, Feagan B, Ma C . Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease. BioDrugs. 2020; 34(6):713-721. DOI: 10.1007/s40259-020-00451-w. View

Ananthakrishnan A . Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12(4):205-17. DOI: 10.1038/nrgastro.2015.34. View

Angelison L, Almer S, Eriksson A, Karling P, Fagerberg U, Halfvarson J . Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients. Aliment Pharmacol Ther. 2016; 45(4):519-532. DOI: 10.1111/apt.13893. View

Argollo M, Furfaro F, Gilardi D, Roda G, Allocca M, Peyrin-Biroulet L . Modulation of sphingosine-1-phosphate in ulcerative colitis. Expert Opin Biol Ther. 2020; 20(4):413-420. DOI: 10.1080/14712598.2020.1732919. View

Asano K, Matsushita T, Umeno J, Hosono N, Takahashi A, Kawaguchi T . A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009; 41(12):1325-9. DOI: 10.1038/ng.482. View

Atreya R, Neumann H, Neufert C, Waldner M, Billmeier U, Zopf Y . In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med. 2014; 20(3):313-8. PMC: 4479137. DOI: 10.1038/nm.3462. View

Baird A, Mallon D, Radford-Smith G, Boyer J, Piche T, Prescott S . Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. World J Gastroenterol. 2016; 22(41):9104-9116. PMC: 5107592. DOI: 10.3748/wjg.v22.i41.9104. View

Barberio B, DInca R, Facchin S, Dalla Gasperina M, Fohom Tagne C, Cardin R . Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. Inflamm Bowel Dis. 2019; 26(5):756-763. DOI: 10.1093/ibd/izz195. View

10.

Bek S, Nielsen J, Bojesen A, Franke A, Bank S, Vogel U . Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016; 44(6):554-67. PMC: 5113857. DOI: 10.1111/apt.13736. View

11.

Belarif L, Danger R, Kermarrec L, Nerriere-Daguin V, Pengam S, Durand T . IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. J Clin Invest. 2019; 129(5):1910-1925. PMC: 6486337. DOI: 10.1172/JCI121668. View

12.

Beltran B, Iborra M, Saez-Gonzalez E, Marques-Minana M, Moret I, Cerrillo E . Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease. Dig Dis. 2018; 37(2):108-115. DOI: 10.1159/000492626. View

13.

Beswick L, Rosella O, Rosella G, Headon B, Sparrow M, Gibson P . Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. J Crohns Colitis. 2017; 12(3):289-297. DOI: 10.1093/ecco-jcc/jjx146. View

14.

Blaho V, Hla T . An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014; 55(8):1596-608. PMC: 4109755. DOI: 10.1194/jlr.R046300. View

15.

Bogaert S, Laukens D, Peeters H, Melis L, Olievier K, Boon N . Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol. 2010; 11:61. PMC: 3016394. DOI: 10.1186/1471-2172-11-61. View

16.

Bosca-Watts M, Tosca J, Anton R, Mora M, Minguez M, Mora F . Pathogenesis of Crohn's disease: Bug or no bug. World J Gastrointest Pathophysiol. 2015; 6(1):1-12. PMC: 4325296. DOI: 10.4291/wjgp.v6.i1.1. View

17.

Burns R, Rivera-Nieves J, Moskaluk C, Matsumoto S, Cominelli F, Ley K . Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology. 2001; 121(6):1428-36. DOI: 10.1053/gast.2001.29568. View

18.

Caenepeel C, Sadat Seyed Tabib N, Vieira-Silva S, Vermeire S . Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease. Aliment Pharmacol Ther. 2020; 52(9):1453-1468. DOI: 10.1111/apt.16096. View

19.

Caneparo V, Pastorelli L, Pisani L, Bruni B, Prodam F, Boldorini R . Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. Inflamm Bowel Dis. 2016; 22(12):2977-2987. DOI: 10.1097/MIB.0000000000000926. View

20.

Cepek K, Shaw S, Parker C, Russell G, Morrow J, Rimm D . Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. Nature. 1994; 372(6502):190-3. DOI: 10.1038/372190a0. View